Research programme: adult stem cell therapies - DaVinci Biosciences
Latest Information Update: 28 Nov 2020
Price :
$50 *
At a glance
- Originator DaVinci Biosciences
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cardiovascular disorders; Cartilage disorders; Neurological disorders
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Nov 2020 No recent reports of development identified for research development in Cartilage-disorders in USA (Parenteral)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral)